Thomas S Griffith

List of Publications by Year
in descending order

149 papers	12,454 citations	36303 51 h-index	26613 107 g-index
155 all docs	155 docs citations	155 times ranked	13803 citing authors

#	Article	IF	Citations
1	Tumoricidal activity of tumor necrosis factorâ€“related apoptosisâ€“inducing ligand in vivo. Nature Medicine, 1999, 5, 157-163.	30.7	2,377
2	Intravascular staining for discrimination of vascular and tissue leukocytes. Nature Protocols, 2014, 9, 209-222.	12.0	612
3	CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature, 2005, 434, 88-93.	27.8	547
4	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine, 2019, 25, 141-151.	30.7	539
5	Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factorâ€“related Cytokine, TRAIL. Journal of Experimental Medicine, 1999, 189, 1343-1354.	8.5	442
6	TRAIL: a molecule with multiple receptors and control mechanisms. Current Opinion in Immunology, 1998, 10, 559-563.	5.5	436
7	Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand (Trail). Journal of Experimental Medicine, 1999, 190, 1155-1164.	8.5	369
8	CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance. Immunity, 1996, 5, 7-16.	14.3	366
9	Antiinflammatory Effects of CD95 Ligand (FasL)-induced Apoptosis. Journal of Experimental Medicine, 1998, 188, 887-896.	8.5	208
10	Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research, 2002, 62, 7170-4.	0.9	201
11	Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis. Journal of Immunology, 2000, 165, 2886-2894.	0.8	184
12	CD8 T Cells Utilize TRAIL to Control Influenza Virus Infection. Journal of Immunology, 2008, 181, 4918-4925.	0.8	176
13	Uptake of Apoptotic Antigen-Coupled Cells by Lymphoid Dendritic Cells and Cross-Priming of CD8+ T Cells Produce Active Immune Unresponsiveness. Journal of Immunology, 2002, 168, 5589-5595.	0.8	174
14	A vision of cell death: insights into immune privilege. Immunological Reviews, 1997, 156, 167-184.	6.0	167
15	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Cancer Research, 2004, 64, 3386-3390.	0.9	167
16	TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. European Journal of Pharmacology, 2009, 625, 63-72.	3.5	163
17	Inducible Nonlymphoid Expression of Fas Ligand Is Responsible for Superantigen-Induced Peripheral Deletion of T Cells. Immunity, 1998, 9, 711-720.	14.3	145
18	Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity. Journal of Immunology, 2018, 200, 1543-1553.	0.8	143

#	Article	IF	Citations
19	Cellular Inhibitor of Apoptosis Protein cIAP2 Protects against Pulmonary Tissue Necrosis during Influenza Virus Infection to Promote Host Survival. Cell Host and Microbe, 2014, 15, 23-35.	11.0	141
20	Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials, 2018, 164, 38-53.	11.4	133
21	Impact of sepsis on CD4 T cell immunity. Journal of Leukocyte Biology, 2014, 96, 767-777.	3.3	128
22	Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guèrin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood, 2005, 106, 3474-3482.	1.4	112
23	A vision of cell death: Fas ligand and immune privilege 10 years later. Immunological Reviews, 2006, 213, 228-238.	6.0	101
24	Role of neutrophils in BCG immunotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 341-345.	1.6	100
25	TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site. Journal of Immunology, 2002, 169, 4739-4744.	0.8	95
26	Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation. Journal of Immunology, 2004, 173, 892-899.	0.8	95
27	Diet-Induced Obesity Alters Dendritic Cell Function in the Presence and Absence of Tumor Growth. Journal of Immunology, 2012, 189, 1311-1321.	0.8	94
28	Suppression of Tumor Growth Following Intralesional Therapy with TRAIL Recombinant Adenovirus. Molecular Therapy, 2001, 4, 257-266.	8.2	90
29	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. Journal of Leukocyte Biology, 2005, 77, 378-387.	3.3	90
30	Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying Cells. Immunity, 2011, 35, 456-466.	14.3	86
31	TRAIL Gene Therapy: From Preclinical Development to Clinical Application. Current Gene Therapy, 2009, 9, 9-19.	2.0	84
32	CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State. Frontiers in Immunology, 2020, 11, 1364.	4.8	83
33	Depsipeptide (FR901228) Enhances the Cytotoxic Activity of TRAIL by Redistributing TRAIL Receptor to Membrane Lipid Rafts. Molecular Therapy, 2005, 11, 542-552.	8.2	81
34	Apoptotic Cells Induce Tolerance by Generating Helpless CD8+ T Cells That Produce TRAIL. Journal of Immunology, 2007, 178, 2679-2687.	0.8	81
35	Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Resistant Bladder Tumor Cells. Cancer Research, 2006, 66, 499-507.	0.9	80
36	TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. Journal of Experimental Medicine, 2012, 209, 1937-1952.	8.5	79

#	Article	IF	Citations
37	Microbial Exposure Enhances Immunity to Pathogens Recognized by TLR2 but Increases Susceptibility to Cytokine Storm through TLR4 Sensitization. Cell Reports, 2019, 28, 1729-1743.e5.	6.4	74
38	Sustained and Incomplete Recovery of Naive CD8+ T Cell Precursors after Sepsis Contributes to Impaired CD8+ T Cell Responses to Infection. Journal of Immunology, 2013, 190, 1991-2000.	0.8	73
39	Plasmacytoid Dendritic Cell-Derived IFN-Î± Induces TNF-Related Apoptosis-Inducing Ligand/Apo-2L-Mediated Antitumor Activity by Human Monocytes Following CpG Oligodeoxynucleotide Stimulation. Journal of Immunology, 2003, 171, 212-218.	0.8	67
40	Therapeutic applications of TRAIL receptor agonists in cancer and beyond. , 2015, 155, 117-131.		67
41	Sepsis-Induced Apoptosis Leads to Active Suppression of Delayed-Type Hypersensitivity by CD8+ Regulatory T Cells through a TRAIL-Dependent Mechanism. Journal of Immunology, 2010, 184, 6766-6772.	0.8	63
42	Regulation of Fas Ligand-Induced Apoptosis by TNF. Journal of Immunology, 2001, 167, 3049-3056.	0.8	62
43	Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Research, 2002, 62, 3093-9.	0.9	60
44	Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biology and Therapy, 2005, 4, 1104-1112.	3.4	59
45	Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy. Nanoscale, 2018, 10, 20851-20862.	5.6	59
46	New Insights into the Immune System Using Dirty Mice. Journal of Immunology, 2020, 205, 3-11.	0.8	59
47	The Plasticity of Regulatory T Cell Function. Journal of Immunology, 2011, 187, 4987-4997.	0.8	58
48	Polymicrobial Sepsis Alters Antigen-Dependent and -Independent Memory CD8 T Cell Functions. Journal of Immunology, 2014, 192, 3618-3625.	0.8	58
49	TRAIL Deficiency Delays, but Does Not Prevent, Erosion in the Quality of â€œHelplessâ€•Memory CD8 T Cells. Journal of Immunology, 2006, 177, 999-1006.	0.8	56
50	Immune Unresponsiveness to Secondary Heterologous Bacterial Infection after Sepsis Induction Is TRAIL Dependent. Journal of Immunology, 2011, 187, 2148-2154.	0.8	56
51	Apoptosis, tolerance, and regulatory T cells - old wine, new wineskins. Immunological Reviews, 2003, 193, 111-123.	6.0	55
52	Alterations in Antigen-Specific Naive CD4 T Cell Precursors after Sepsis Impairs Their Responsiveness to Pathogen Challenge. Journal of Immunology, 2015, 194, 1609-1620.	0.8	55
53	Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity. Critical Reviews in Immunology, 2016, 36, 57-74.	0.5	55
54	Inhibition of the NF-Î¤B pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Therapy, 2004, 11, 681-690.	4.6	54

#	Article	IF	Citations
55	Cutting Edge: Elevated Leptin during Diet-Induced Obesity Reduces the Efficacy of Tumor Immunotherapy. Journal of Immunology, 2018, 201, 1837-1841.	0.8	53
56	Immunosuppression after Sepsis: Systemic Inflammation and Sepsis Induce a Loss of NaÃ¯ve T-Cells but No Enduring Cell-Autonomous Defects in T-Cell Function. PLoS ONE, 2014, 9, e115094.	2.5	52
57	Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease. Experimental Biology and Medicine, 2017, 242, 127-139.	2.4	51
58	Neisseria gonorrhoeae delays the onset of apoptosis in polymorphonuclear leukocytes. Cellular Microbiology, 2006, 8, 1780-1790.	2.1	49
59	Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion. Journal of Immunology, 2015, 195, 116-125.	0.8	48
60	Polymicrobial Sepsis Diminishes Dendritic Cell Numbers and Function Directly Contributing to Impaired Primary CD8 T Cell Responses In Vivo. Journal of Immunology, 2016, 197, 4301-4311.	0.8	48
61	Polymicrobial Sepsis Chronic Immunoparalysis Is Defined by Diminished Ag-Specific T Cell-Dependent B Cell Responses. Frontiers in Immunology, 2018, 9, 2532.	4.8	48
62	Polymicrobial sepsis impairs bystander recruitment of effector cells to infected skin despite optimal sensing and alarming function of skin resident memory CD8 T cells. PLoS Pathogens, 2017, 13, e1006569.	4.7	47
63	Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy. PLoS ONE, 2012, 7, e31085.	2.5	46
64	Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections. PLoS Pathogens, 2018, 14, e1007405.	4.7	46
65	Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy. Cancer Research, 2007, 67, 11980-11990.	0.9	45
66	Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 561-571.	4.9	45
67	The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmetteâ€“GuÃ©rin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer and Metastasis Reviews, 2009, 28, 345-353.	5.9	44
68	T-Cell-Mediated Immunity and the Role of TRAIL in Sepsis-Induced Immunosuppression. Critical Reviews in Immunology, 2013, 33, 23-40.	0.5	43
69	Therapeutic potential of VIP vs PACAP in diabetes. Journal of Molecular Endocrinology, 2012, 49, R157-R167.	2.5	41
70	Clinical utility of insulin and insulin analogs. Islets, 2013, 5, 67-78.	1.8	40
71	The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse. Journal of Immunology, 2015, 194, 5926-5936.	0.8	40
72	Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils. Infection and Immunity, 2007, 75, 1265-1271.	2.2	39

#	Article	IF	Citations
73	Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunologic Research, 2007, 39, 79-93.	2.9	39
74	Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Experimental Hematology, 2004, 32, 1073-1081.	0.4	38
75	PMN and anti-tumor immunityâ€"The case of bladder cancer immunotherapy. Seminars in Cancer Biology, 2013, 23, 183-189.	9.6	38
76	Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 715-724.	2.5	38
77	The Magnitude of the T Cell Response to a Clinically Significant Dose of Influenza Virus Is Regulated by TRAIL. Journal of Immunology, 2011, 187, 4581-4588.	0.8	36
78	Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 158-165.	1.6	33
79	TRAIL deletion prevents liver inflammation but not adipose tissue inflammation during murine dietâ€induced obesity. Hepatology Communications, 2017, 1, 648-662.	4.3	33
80	CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunology, Immunotherapy, 2014, 63, 1213-1227.	4.2	32
81	Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8. ACS Medicinal Chemistry Letters, 2017, 8, 1148-1152.	2.8	32
82	Adenovirus-Mediated TRAIL Gene (Ad5hTRAIL) Delivery into Pancreatic Islets Prolongs Normoglycemia in Streptozotocin-Induced Diabetic Rats. Human Gene Therapy, 2009, 20, 1177-1189.	2.7	31
83	Gut Microbial Membership Modulates CD4 T Cell Reconstitution and Function after Sepsis. Journal of Immunology, 2016, 197, 1692-1698.	0.8	31
84	High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients. Pancreas, 2009, 38, 154-160.	1.1	30
85	Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Molecular Pharmaceutics, 2019, 16, 1200-1210.	4.6	30
86	The immune response and the eye. TCR Â-chain related molecules regulate the systemic immunity to antigen presented in the eye. International Immunology, 1995, 7, 1617-1625.	4.0	29
87	Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. Journal of Pediatric Surgery, 2006, 41, 1431-1440.	1.6	29
88	Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses. Journal of the National Cancer Institute, 2001, 93, 998-1007.	6.3	28
89	Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 13-26.	4.9	28
90	TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Molecular Pharmaceutics, 2020, 17, 2109-2124.	4.6	28

#	Article	IF	Citations
91	Molecular mechanisms of death ligandâ€mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Journal of Cellular Biochemistry, 2008, 104, 710-720.	2.6	27
92	High Levels of Endogenous Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression Correlate With Increased Cell Death in Human Pancreas. Pancreas, 2008, 36, 385-393.	1.1	27
93	TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. Journal of Leukocyte Biology, 2008, 83, 621-629.	3.3	26
94	Inducing Experimental Polymicrobial Sepsis by Cecal Ligation and Puncture. Current Protocols in Immunology, 2020, 131, e110.	3.6	25
95	Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. Human Immunology, 2008, 69, 634-646.	2.4	24
96	Activation-Induced CD154 Expression Abrogates Tolerance Induced by Apoptotic Cells. Journal of Immunology, 2009, 183, 6114-6123.	0.8	24
97	Systemic Immunological Tolerance to Ocular Antigens Is Mediated by TRAIL-Expressing CD8+ T Cells. Journal of Immunology, 2011, 186, 791-798.	0.8	24
98	Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells. ACS Nano, 2018, 12, 6563-6576.	14.6	24
99	Structure/Function Analysis of the Murine CD95L Promoter Reveals the Identification of a Novel Transcriptional Repressor and Functional CD28 Response Element. Journal of Biological Chemistry, 2003, 278, 35950-35958.	3.4	22
100	Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Current Opinion in Investigational Drugs, 2010, 11, 688-98.	2.3	22
101	Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cellâ€“Mediated Antitumor Immunity. Journal of Immunology, 2019, 203, 725-735.	0.8	21
102	Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival. Journal of Immunology, 2019, 202, 2843-2848.	0.8	20
103	Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8Î± dendritic cells. Cancer Immunology, Immunotherapy, 2014, 63, 685-697.	4.2	19
104	Minimal changes in the systemic immune response after nephrectomy of localized renal masses11This work was supported by the University of Iowa Carver College of Medicine/Department of Urology Investigator Start-up Funds, NIH Grant CA181088-01 (to L.A.N.), and NIH Grant CA109446 (to T.S.G.).. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 589-600.	1.6	19
105	NK Cellâ€“Derived IL-10 Supports Host Survival during Sepsis. Journal of Immunology, 2021, 206, 1171-1180.	0.8	19
106	Sepsis leads to lasting changes in phenotype and function of memory CD8 T cells. ELife, 2021, 10, .	6.0	19
107	TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion. Journal of Leukocyte Biology, 2010, 88, 1217-1225.	3.3	18
108	Polymicrobial Sepsis Impairs Antigen-Specific Memory CD4 T Cell-Mediated Immunity. Frontiers in Immunology, 2020, 11, 1786.	4.8	18

#	Article	IF	Citations
109	TRAIL-Deficient Mice Exhibit Delayed Regression of Retinal Neovascularization. American Journal of Pathology, 2009, 175, 2697-2708.	3.8	17
110	Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Scientific Reports, 2021, 11, 3346.	3.3	17
111	Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 1612-1620.	3.3	16
112	A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies. Journal of Visualized Experiments, 2017, , .	0.3	16
113	Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes. Human Gene Therapy, 2018, 29, 802-815.	2.7	16
114	Sepsis impedes EAE disease development and diminishes autoantigen-specific naive CD4 T cells. ELife, 2020, 9, .	6.0	16
115	Cell death and the immune response: a lesson from the privileged. Journal of Clinical Immunology, 1997, 17, 1-10.	3.8	15
116	Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-Î± combination therapy. International Journal of Cancer, 2006, 119, 2632-2641.	5.1	15
117	Triptolide enhances the tumoricidal activity of <scp>TRAIL</scp> against renal cell carcinoma. FEBS Journal, 2015, 282, 4747-4765.	4.7	15
118	The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemotherapy and Pharmacology, 2003, 52, 175-184.	2.3	14
119	GLP-1-mediated gene therapy approaches for diabetes treatment. Expert Reviews in Molecular Medicine, 2014, 16, e7.	3.9	14
120	The current status of immunobased therapies for metastatic renal-cell carcinoma. ImmunoTargets and Therapy, 2017, Volume 6, 83-93.	5.8	14
121	Prolonged Reactive Oxygen Species Production following Septic Insult. ImmunoHorizons, 2021, 5, 477-488.	1.8	14
122	Sepsis, Cytokine Storms, and Immunopathology: The Divide between Neonates and Adults. ImmunoHorizons, 2021, 5, 512-522.	1.8	14
123	HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. Gene Therapy, 2018, 25, 269-283.	4.5	12
124	Tracing of islet graft survival by way of in vivo fluorescence imaging. Diabetes/Metabolism Research and Reviews, 2011, 27, 575-583.	4.0	11
125	Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Cancers, 2011, 3, 603-620.	3.7	11
126	Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses. Journal of Virology, 2019, 93, .	3.4	11

#	Article	IF	Citations
127	The Use of Immunofluorescence in Microdissection Testicular Sperm Extraction. Journal of Andrology, 2009, 30, 548-551.	2.0	10
128	Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes. Molecular Therapy, 2021, 29, 149-161.	8.2	10
129	Severity of Sepsis Determines the Degree of Impairment Observed in Circulatory and Tissue-Resident Memory CD8 T Cell Populations. Journal of Immunology, 2021, 207, 1871-1881.	0.8	10
130	Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. Cell Death and Disease, 2018, 8, e2535-e2535.	6.3	9
131	Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation. Gene Therapy, 2021, 28, 130-141.	4.5	9
132	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Human Gene Therapy, 2021, 32, 541-562.	2.7	9
133	Cytomegalovirus and the role of interferon in the expression of tumor necrosis factorâ€“related apoptosis-inducing ligand in the placenta. American Journal of Obstetrics and Gynecology, 2007, 197, 608.e1-608.e6.	1.3	8
134	CD8 T Cellâ€“Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers, 2016, 8, 71.	3.7	8
135	Exploiting antibody biology for the treatment of cancer. Immunotherapy, 2020, 12, 255-267.	2.0	7
136	Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats. Asian Journal of Andrology, 2009, 11, 373-378.	1.6	6
137	Worry and FRET: ROS Production Leads to Fluorochrome Tandem Degradation and impairs Interpretation of Flow Cytometric Results. Immunity, 2020, 52, 419-421.	14.3	6
138	CD8⁺ T cells mediate ultraviolet Aâ€induced immunomodulation in a model of extracorporeal photochemotherapy. European Journal of Immunology, 2020, 50, 725-735.	2.9	6
139	A wild microbiome improves mouse modeling of the human immune response. Lab Animal, 2019, 48, 337-338.	0.4	5
140	Sepsis and multiple sclerosis: Causative links and outcomes. Immunology Letters, 2021, 238, 40-46.	2.5	5
141	Activation of systemic antitumor immunity via TRAIL-induced apoptosis. OncoImmunology, 2012, 1, 1178-1180.	4.6	4
142	Induction of Tumor Cell Apoptosis by TRAIL Gene Therapy. Methods in Molecular Biology, 2009, 542, 315-334.	0.9	4
143	Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs. Bioorganic and Medicinal Chemistry Letters, 2022, 59, 128548.	2.2	4
144	Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic pathways in cancer immunosurveillance: molecular mechanisms and prospects for therapy. Research and Reports in Biochemistry, 2014, , 1.	1.6	3

#	Article	IF	Citations
145	Autoimmunity Increases Susceptibility to and Mortality from Sepsis. ImmunoHorizons, 2021, 5, 844-854.	1.8	3
146	Description of a Novel Murine Model for Ileocystoplasty and Early Histologic Changes. Scientific World Journal, The, 2011, 11, 1325-1331.	2.1	2
147	The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer. Immunotherapy, 2017, 9, 1005-1018.	2.0	2
148	Micro-recanalization in a biodegradable graft for reconstruction of the vas deferens is enhanced by sildenafil citrate. Asian Journal of Andrology, 2010, 12, 814-818.	1.6	1
149	Focal Therapy for Prostate Cancer: A Molecular Biology Approach with TRAIL. Current Clinical Urology, 2017, , 347-354.	0.0	0